JP2005501121A - ヒドラジノペプトイドおよび癌を処置するためのそれらの使用 - Google Patents

ヒドラジノペプトイドおよび癌を処置するためのそれらの使用 Download PDF

Info

Publication number
JP2005501121A
JP2005501121A JP2003523221A JP2003523221A JP2005501121A JP 2005501121 A JP2005501121 A JP 2005501121A JP 2003523221 A JP2003523221 A JP 2003523221A JP 2003523221 A JP2003523221 A JP 2003523221A JP 2005501121 A JP2005501121 A JP 2005501121A
Authority
JP
Japan
Prior art keywords
group
formula
compound
cor
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003523221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501121A5 (enExample
Inventor
ボンメー，ヤニック
ブジェ，カリーヌ
フロック，ミシェル
ル・グレル，フィリップ
オービン，サンドリーヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Original Assignee
Centre National de la Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique filed Critical Centre National de la Recherche Scientifique
Publication of JP2005501121A publication Critical patent/JP2005501121A/ja
Publication of JP2005501121A5 publication Critical patent/JP2005501121A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/20—Quaternary compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/34—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a carbon skeleton further substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2003523221A 2001-08-27 2002-08-27 ヒドラジノペプトイドおよび癌を処置するためのそれらの使用 Pending JP2005501121A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0111120A FR2828884B1 (fr) 2001-08-27 2001-08-27 Hydrazinopeptoides et leurs utilisations dans le traitement des cancers
PCT/FR2002/002935 WO2003018557A1 (fr) 2001-08-27 2002-08-27 Hydrazinopeptoides et leurs utilisations dans le traitement des cancers

Publications (2)

Publication Number Publication Date
JP2005501121A true JP2005501121A (ja) 2005-01-13
JP2005501121A5 JP2005501121A5 (enExample) 2005-12-22

Family

ID=8866739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003523221A Pending JP2005501121A (ja) 2001-08-27 2002-08-27 ヒドラジノペプトイドおよび癌を処置するためのそれらの使用

Country Status (6)

Country Link
US (1) US20040142851A1 (enExample)
EP (1) EP1421065A1 (enExample)
JP (1) JP2005501121A (enExample)
CA (1) CA2430267A1 (enExample)
FR (1) FR2828884B1 (enExample)
WO (1) WO2003018557A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2855971B1 (fr) * 2003-06-11 2013-01-11 Centre Nat Rech Scient Analogues peptidiques comprenant au moins un residu aza-beta3-aminoacyle, et leurs utilisations, notamment en therapie
FR2859995A1 (fr) * 2003-09-23 2005-03-25 Centre Nat Rech Scient Hydrazinopeptoides reduits et leurs utilisations dans le traitement des cancers
US8236783B2 (en) * 2006-08-15 2012-08-07 Duke University ROS-sensitive iron chelators and methods of using the same
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
CA2862580A1 (en) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to nae inhibitors
EP2776586B1 (en) 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013112601A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
US10662477B2 (en) 2012-10-01 2020-05-26 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
EP2986290A4 (en) 2013-04-19 2017-01-04 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
US20190055283A1 (en) * 2016-02-29 2019-02-21 Ohio State Innovation Foundation Aza-peptide aldehydes and ketones

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203932A (en) * 1979-03-01 1980-05-20 Gaf Corporation Phosphoryl hydrazines
SU1613508A1 (ru) * 1988-03-28 1990-12-15 Институт Химии Ан Мсср Стабилизатор электролита железнени
CA2036770C (en) * 1990-02-26 2003-09-09 Jeffrey P. Whitten Inhibitors of nitric oxide biosynthesis
WO1995018186A1 (en) * 1993-12-28 1995-07-06 Arqule Partners, L.P. Modular design and synthesis of aminimide containing molecules
DE19932796A1 (de) * 1999-07-14 2001-01-18 Merck Patent Gmbh Diacylhydrazinderivate

Also Published As

Publication number Publication date
CA2430267A1 (fr) 2003-03-06
FR2828884B1 (fr) 2005-09-09
EP1421065A1 (fr) 2004-05-26
US20040142851A1 (en) 2004-07-22
WO2003018557A1 (fr) 2003-03-06
FR2828884A1 (fr) 2003-02-28

Similar Documents

Publication Publication Date Title
CA2703491C (en) Tubulysins and processes for preparing
Capone et al. Electrophilic S‐Trifluoromethylation of Cysteine Side Chains in α‐and β‐Peptides: Isolation of Trifluoro‐methylated Sandostatin®(Octreotide) Derivatives
EP2444411B1 (en) Tripeptide boronic acid or boronic ester, preparative method and use thereof
CA2338524C (en) Inhibitors of urokinase and blood vessel formation
US6271232B1 (en) Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use
JP4144811B2 (ja) ペプチジル−２−アミノ−１−ヒドロキシアルカンスルホン酸システインプロテアーゼインヒビター
FR2518088A1 (fr) Nouveaux derives d'aminoacides, et leur application therapeutique
FR2609289A1 (fr) Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
AU4111700A (en) Low-molecular inhibitors of complement proteases
JP2021526159A (ja) ペプチドボロン酸エステル類化合物の合成及び使用
US20040142851A1 (en) Hydrazinopeptoids and their uses for treating cancers
JP2021178855A (ja) ヒストンデアセチラーゼの阻害剤としての大環状分子のチオエステルプロドラッグ
JP2005501121A5 (enExample)
Korotkov et al. Synthesis and biological activity of optimized belactosin C congeners
JPH08301831A (ja) スチルベン誘導体及びそれを含有する制癌剤
US6992207B2 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
CA2413035A1 (en) Thrombin inhibitors comprising an aminoisoquinoline group
US6649593B1 (en) Modulators of SREBP processing
CA2779949A1 (en) Peptidomimetics comprising n-amino cyclic urea residues and uses thereof
CN118561953A (zh) 一种大环炔基硫醚肽类化合物及其制备方法与应用
JPH07316193A (ja) ペプチド誘導体およびその用途
US20240254098A1 (en) Thioester prodrugs for the treatment of renal anomalies
WO2021244297A1 (zh) 含酰肼结构的pd-l1环肽抑制剂
JPH06279489A (ja) 新規オカダ酸誘導体
HK1025511B (en) Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090421